Modeling PAH Toxicity in Sediments Clause Samples

Modeling PAH Toxicity in Sediments. The concentrations of selected PAHs in the sediments of Port ▇▇▇▇▇▇ have been identified in samples collected during several monitoring and research studies. Sampling sites included the Small Boat Harbor (U.S. ACE, 1995), offshore of the Valdez Marine Terminal and Gold Creek (▇▇▇▇▇ and Shaw, 1993, 1994b, 1995, and 1996; Kinnetics Laboratories Inc., 1995), near Solomon Gulch Hatchery (unpublished data., ▇▇▇▇▇ ▇▇▇▇, University of Alaska Fairbanks, 1996), and other deep water areas of the Port (▇▇▇▇▇ and Shaw, 1993, 1994b, 1995, and 1996). These measured concentrations provided input for the ∑PAH model developed by ▇▇▇▇▇▇ et al. (1995). The steps of the model are shown in Figure 2-4. This model combines five well-known models to assess the risk due to hydrocarbons in the sediments. 1. Equilibrium Partitioning model: describes the partitioning of PAH in the sediment interstitial water based on the total organic carbon content of the sediments 2. QSAR model: determines the acute toxicity of individual PAHs to amphipods in a 10-day test 3. Toxic Unit model: describes the toxicity of the PAHs in the interstitial water 4. Additivity model: determines the total toxicity from 13 selected PAHs 5. Concentration-response model: describes the mortality response of amphipods to spiked field sediments The model predicts the probability of no toxicity (defined as <13% mortality), uncertain toxicity (defined as 13-24% mortality), and toxicity (defined as >24% toxicity). The model input, output and calculations can be found in Appendix E. The results are described in Section 7.2.
View Source

Related to Modeling PAH Toxicity in Sediments

  • Groundwater Any water, except capillary moisture, beneath the land surface or beneath the bed of any stream, lake, reservoir or other body of surface water within the boundaries of this state, whatever may be the geologic formation or structure in which such water stands, flows, percolates, or otherwise moves.

  • ENDANGERED SPECIES The Endangered Species Act of 1973 (16 U.S.C. § 1531, et seq.) as amended, particularly section 7 (16 U.S.C. § 1536).

  • Contamination The presence in, on or under land, air or water of a substance (whether a solid, liquid, gas, odour, heat, sound, vibration or radiation) at a concentration above the concentration at which the substance is normally present in, on or under land, air or water in the same locality, that presents a risk of Environmental Harm, including harm to human health or any other aspect of the Environment, or could otherwise give rise to a risk of non-compliance with any Statutory Requirement for the protection of the Environment.

  • Sampling The Licensee agrees that the Composition is purchased as a “Work Made for Hire” whereby the clearing of any sampled materials is the responsibility of Licensee.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.